Automated homogeneous immunoassay for gentamicin on the dimension clinical chemistry system

Clinical Chemistry

Volumn 45, Issue 3, 1999, Pages 388-393

  Wei, Tie Q ^a   Chu, Victor P ^a   Craig, Alan R ^a   Duffy, James E ^a   Obzansky, David M ^a   Kilgore, Daniel ^a   Masulli, Ignazio S ^a   Sanders, Connie M ^a   Thompson, John C ^a  

^a SIEMENS CORPORATE RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBENICILLIN; CEFALOTIN; GENTAMICIN; GENTAMICIN FLEX; HEPARIN; KANAMYCIN A; KANAMYCIN B; MICRONOMICIN; MONOCLONAL ANTIBODY; NEOMYCIN; NETILMICIN; PENICILLIN G; REAGENT; SISOMICIN; STREPTOMYCIN; SULFANILAMIDE; TETRACYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOANALYSIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON;

EID: 0032913626     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.3.388     Document Type: Article

References (20)

1. 1. Keys TF, Kurtz SB, Jones JD. Renal toxicity during therapy with gentamicin or tobramycin. Mayo Clin Proc 1981;56:556-9.
2. 2. Schentag JJ. Aminoglycosides. In: Evans W, Schentag J, Jusko W, eds. Applied pharmacokinetics. San Francisco, CA: Applied Therapeutics, 1980:174-209.
3. 3. Zaske DE, Cipolle RJ, Strate RG. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery 1980;87:164-9.
4. 4. Dudley PA, Edwards P, Ekins RP, Finney DJ, McKenzie IGM, Raad GM, et al. Guidelines for immunoassay data processing. Clin Chem 1985;31:1264-71.
5. 5. Litchfiled WJ, Craig AR, Frey WA, Leflar CC, Looney CE, Lluddy MA. Novel shell/core particles for automated immunoassays. Clin Chem 1984;30:1489-93.
6. 6. Burtis C, Ashwood E. Tietz textbook of clinical chemistry, 2nd ed. Philadelphia, PA: WB Saunders, 1994:1131pp.
7. 7. Kahn M. The history of rheumatoid factor. Rev Rhum Engl Ed 1995;62:7-8.
8. 8. Boscato LM, Stuart MC. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988;34:27-33.
9. 9. Hansen HJ, LaFontaine G, Newman ES, Schwartz MK, Malkin A, Majozisik K, et al. Solving the problem of antibody interference in commercial "sandwich"-type immunoassays of carcinoembryonic antigen. Clin Chem 1989;35:145-51.
10. 10. Nahm HM, Hoffmann JW. Heteroantibody: phantom of the immunoassay. Clin Chem 1990;36:6.
11. 11. Craig AR. A novel mechanism for latex agglutination assays [Abstract]. 67th Annual CIC Conference. Ottawa, Canada: Chemical Institute of Canada, 1984:M57-05.
12. 12. Thompson JC, Craig AR, Davey CL, Newman DJ, Lonsdale ML, Bucher WJ, et al. Kinetics and proposed mechanism of the reaction of an immunoinhibition, particle-enhanced immunoassay. Clin Chem 1997;43:2384-9.
13. 2 suitable for clinical use from mouse lgG1. Mol Immunol 1991;28:69-77.
14. 14. Koehler G, Milstein C. Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature 1975;256:495-7.
15. 15. Anhalt JP, Sancilio FD, McCorkle T. Gentamicin C-component ratio determination by high-pressure liquid chromatography. J Chromatogr 1978;153:389-493.
16. 2 conjugate and polyclonal mouse lgG. Clin Chem 1992;38:1737-42.
17. 17. Knight D, Singer R, White JM, Fraser CG. Laboratory evaluation of the DuPont Clinical Chemistry System. Clin Chem 1988;34: 1899-903.
18. 18. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of agreement. Lancet 1986;i:307-10.
19. 19. Peterson PH, Stockl D, Blaabjerg O, Pedersen B, Birkenose E, Thienpont L, et al. Graphical interpretation of analytical data from comparison of a field method with a reference method by use of difference plots. Clin Chem 1997;43:2039-46.
20. 20. Burnett RW. Quantitative evaluation of linearity. Clin Chem 1980; 26:44-6.